Varct receives funds for cancer research – in talks with potential partners

Varct Diagnostics, which is developing a method to detect cancer from a single blood sample, has received DKK 15 million from the Innovation Fund Denmark, to be spent on fully developing the method and validating it for humans next year. The goal is to license the technology to a major international diagnostics firm, and talks are ongoing, says CEO.

Ali Salanti, CEO at Varct Diagnostics and Var2 Pharmaceuticals. Photo: Christian Brasen

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles